Asset Details
Do you wish to reserve the book?
Additive effect of erythropoietin use on exercise-induced endothelial activation and hypercoagulability in athletes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Additive effect of erythropoietin use on exercise-induced endothelial activation and hypercoagulability in athletes
Do you wish to request the book?
Additive effect of erythropoietin use on exercise-induced endothelial activation and hypercoagulability in athletes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Additive effect of erythropoietin use on exercise-induced endothelial activation and hypercoagulability in athletes
2020
Overview
Purpose
Recombinant human erythropoietin (rHuEPO) is known to increase thrombotic risk in patients and might have similar effects in athletes abusing the drug. rHuEPO is prohibited by anti-doping legislation, but this risk has not been investigated thoroughly. This analysis was designed to evaluate whether rHuEPO impacts hemostatic profile and endothelial and platelet activation markers in trained subjects, and whether the combination with exercise affects exercise induced alterations.
Methods
This double-blind, randomized, placebo-controlled trial enrolled healthy, trained male cyclists aged 18–50 years. Participants were randomly allocated (1:1) to receive subcutaneous injections of rHuEPO (epoetin-β; mean dose 6000 IU per week) or placebo (0.9% NaCl) for 8 weeks. Subjects performed five maximal exercise tests and a road race, coagulation and endothelial/platelet markers were measured at rest and directly after each exercise effort.
Results
rHuEPO increased P-selectin (+ 7.8% (1.5–14.5),
p
= 0.02) and E-selectin (+ 8.6% (2.0–15.7),
p
= 0.01) levels at rest. Maximal exercise tests significantly influenced all measured coagulation and endothelial/platelet markers, and in the rHuEPO group maximal exercise tests led to 15.3% ((7.0–24.3%),
p
= 0.0004) higher E-selectin and 32.1% ((4.6–66.8%),
p
= 0.0207) higher Platelet factor 4 (PF4) levels compared to the placebo group.
Conclusion
In conclusion, rHuEPO treatment resulted in elevated E- and P-selectin levels in trained cyclists, indicating enhanced endothelial activation and/or platelet reactivity. Exercise itself induces hypercoagulability, and the combination of rHuEPO and exercise increased E-selectin and PF4 levels more than either intervention alone. Based on this, exercise potentially increases thrombotic risk, a risk that might be enhanced in combination with rHuEPO use.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Athletes
/ Biomedical and Life Sciences
/ Blood Coagulation - drug effects
/ Endothelium, Vascular - drug effects
/ Endothelium, Vascular - metabolism
/ Erythropoietin - adverse effects
/ Erythropoietin - pharmacology
/ Exercise
/ Humans
/ Male
/ Occupational Medicine/Industrial Medicine
/ Original
